|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/20/21 NTN Buzztime Inc. S-4/A 1/19/21 182:20M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-4/A Pre-Effective Amendment to Registration Statement HTML 4.44M
- Securities for a Merger
2: EX-8.1 Opinion of Counsel re: Tax Matters HTML 60K
3: EX-23.4 Consent of Expert or Counsel HTML 49K
4: EX-23.5 Consent of Expert or Counsel HTML 49K
11: R1 Document and Entity Information HTML 63K
12: R2 Condensed Consolidated Balance Sheets HTML 167K
13: R3 Condensed Consolidated Balance Sheets HTML 78K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 129K
and Comprehensive Loss
15: R5 Condensed Consolidated Statements of Operations HTML 52K
and Comprehensive Loss (Parenthetical)
16: R6 Condensed Consolidated Statements of Shareholders' HTML 118K
Equity
17: R7 Condensed Consolidated Statements of Cash Flows HTML 190K
18: R8 Condensed Balance Sheets (Brooklyn HTML 140K
ImmunoTherapeutics, LLC)
19: R9 Condensed Statements of Operations (Unaudited) HTML 100K
(Brooklyn ImmunoTherapeutics, LLC)
20: R10 Condensed Statements of Changes in Members' Equity HTML 144K
(Brooklyn ImmunoTherapeutics, LLC)
21: R11 Condensed Statements of Cash Flows (Brooklyn HTML 260K
ImmunoTherapeutics, LLC)
22: R12 Basis of Presentation HTML 57K
23: R13 Organization of Company HTML 57K
24: R14 Merger Agreement and Asset Purchase Agreement HTML 56K
25: R15 Covid-19-Update HTML 54K
26: R16 Going Concern Uncertainty HTML 62K
27: R17 Summary of Significant Accounting Policies And HTML 126K
Estimates
28: R18 Restricted Cash HTML 54K
29: R19 Fixed Assets, Net HTML 61K
30: R20 Fair Value of Financial Instruments HTML 57K
31: R21 Accrued Compensation HTML 56K
32: R22 Concentrations of Risk HTML 56K
33: R23 Revenue Recognition HTML 108K
34: R24 Basic and Diluted Earnings Per Common Share HTML 55K
35: R25 Shareholders' Equity HTML 112K
36: R26 Income Taxes HTML 82K
37: R27 Debt HTML 62K
38: R28 Long-term Debt HTML 55K
39: R29 Leases HTML 106K
40: R30 Commitments and Contingencies HTML 54K
41: R31 Disposition of Site Equipment to Be Installed and HTML 56K
Fixed Assets
42: R32 Software Development Costs HTML 55K
43: R33 Goodwill HTML 62K
44: R34 Accumulated Other Comprehensive Income HTML 55K
45: R35 Recent Accounting Pronouncements HTML 60K
46: R36 Retirement Savings Plan HTML 52K
47: R37 Subsequent Events HTML 61K
48: R38 Organization and Description of Business HTML 61K
Operations (Brooklyn ImmunoTherapeutics, LLC)
49: R39 Description of Business (Brooklyn HTML 53K
ImmunoTherapeutics, LLC) (10-K)
50: R40 Going Concern (Brooklyn ImmunoTherapeutics, LLC) HTML 68K
51: R41 Basis of Presentation and Summary of Significant HTML 67K
Accounting Policies (Brooklyn ImmunoTherapeutics,
LLC)
52: R42 Summary of Significant Accounting Policies HTML 146K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
53: R43 Merger With NTN Buzztime, Inc (Brooklyn HTML 55K
ImmunoTherapeutics, LLC)
54: R44 Fair Value of Financial Instruments (Brooklyn HTML 70K
ImmunoTherapeutics, LLC)
55: R45 Business Combination (Brooklyn ImmunoTherapeutics, HTML 58K
LLC) (10-K)
56: R46 Property and Equipment (Brooklyn HTML 71K
ImmunoTherapeutics, LLC)
57: R47 Goodwill and in Process Research and Development HTML 51K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
58: R48 Security Deposits and Other Assets (Brooklyn HTML 53K
ImmunoTherapeutics, LLC)
59: R49 Accrued Expenses (Brooklyn ImmunoTherapeutics, HTML 60K
LLC)
60: R50 Investor Deposits (Brooklyn ImmunoTherapeutics, HTML 51K
LLC) (10-K)
61: R51 Loans Payable (Brooklyn ImmunoTherapeutics, LLC) HTML 63K
62: R52 Loans Payable and Loans Payable to Related Parties HTML 55K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
63: R53 Commitments and Contingencies (Brooklyn HTML 78K
ImmunoTherapeutics, LLC)
64: R54 Stock-Based Compensation (Brooklyn HTML 58K
ImmunoTherapeutics, LLC)
65: R55 Members' Equity (Brooklyn ImmunoTherapeutics, LLC) HTML 53K
66: R56 Stockholders' Deficiency and Members' Equity HTML 71K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
67: R57 Income Tax (Brooklyn ImmunoTherapeutics, LLC) HTML 96K
(10-K)
68: R58 Subsequent Events (Brooklyn ImmunoTherapeutics, HTML 69K
LLC)
69: R59 Summary of Significant Accounting Policies And HTML 176K
Estimates (Policies)
70: R60 Basis of Presentation and Summary of Significant HTML 92K
Accounting Policies (Policies) (Brooklyn
ImmunoTherapeutics, LLC)
71: R61 Summary of Significant Accounting Policies HTML 125K
(Policies) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
72: R62 Summary of Significant Accounting Policies And HTML 114K
Estimates (Tables)
73: R63 Fixed Assets, Net (Tables) HTML 62K
74: R64 Accrued Compensation (Tables) HTML 55K
75: R65 Revenue Recognition (Tables) HTML 113K
76: R66 Shareholders' Equity (Tables) HTML 95K
77: R67 Income Taxes (Tables) HTML 80K
78: R68 Leases (Tables) HTML 91K
79: R69 Goodwill (Tables) HTML 59K
80: R70 Business Combination (Tables) (Brooklyn HTML 55K
ImmunoTherapeutics, LLC) (10-K)
81: R71 Fair Value of Financial Instruments (Tables) HTML 58K
(Brooklyn ImmunoTherapeutics, LLC)
82: R72 Property and Equipment (Tables) (Brooklyn HTML 65K
ImmunoTherapeutics, LLC)
83: R73 Accrued Expenses (Tables) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC)
84: R74 Commitments and Contingencies (Tables) (Brooklyn HTML 54K
ImmunoTherapeutics, LLC) (10-K)
85: R75 Stockholders' Deficiency and Members' Equity HTML 79K
(Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)
86: R76 Income Tax (Tables) (Brooklyn ImmunoTherapeutics, HTML 84K
LLC) (10-K)
87: R77 Basis of Presentation (Details Narrative) HTML 51K
88: R78 Organization of Company (Details Narrative) (10-K) HTML 56K
89: R79 Merger Agreement and Asset Purchase Agreement HTML 70K
(Details Narrative)
90: R80 Covid-19-Update (Details Narrative) HTML 55K
91: R81 Going Concern Uncertainty (Details Narrative) HTML 93K
92: R82 Going Concern Uncertainty (Details Narrative) HTML 73K
(10-K)
93: R83 Summary of Significant Accounting Policies and HTML 195K
Estimates (Details Narrative) (10-K)
94: R84 Summary of Significant Accounting Policies and HTML 73K
Estimates - Schedule of Disaggregation of Revenues
(Details) (10-K)
95: R85 Summary of Significant Accounting Policies and HTML 57K
Estimates - Schedule of Revenues Geographic
Breakdown (Details) (10-K)
96: R86 Summary of Significant Accounting Policies and HTML 61K
Estimates - Schedule of Contract Liabilities
(Details) (10-K)
97: R87 Summary of Significant Accounting Policies and HTML 59K
Estimates - Schedule of Unamortized Installation
Cost and Sales Commissions (Details) (10-K)
98: R88 Restricted Cash (Details Narrative) HTML 68K
99: R89 Restricted Cash (Details Narrative) (10-K) HTML 71K
100: R90 Fixed Assets, Net (Details Narrative) (10-K) HTML 51K
101: R91 Fixed Assets, Net - Schedule of Property and HTML 65K
Equipment (Details) (10-K)
102: R92 Fixed Assets, Net - Schedule of Asset Geographic HTML 54K
Breakdown (Details) (10-K)
103: R93 Accrued Compensation - Schedule of Accrued HTML 61K
Compensation (Details) (10-K)
104: R94 Concentrations of Risk (Details Narrative) (10-K) HTML 71K
105: R95 Revenue Recognition - (Details Narrative) HTML 57K
106: R96 Revenue Recognition - Schedule of Disaggregates HTML 73K
Material Revenue (Details)
107: R97 Revenue Recognition - Schedule of Revenues HTML 57K
Geographic Breakdown (Details)
108: R98 Revenue Recognition - Schedule of Contract HTML 61K
Liabilities (Details)
109: R99 Revenue Recognition - Schedule of Unamortized HTML 59K
Installation Cost and Sales Commissions (Details)
110: R100 Basic and Diluted Earnings Per Common Share HTML 52K
(Details Narrative)
111: R101 Basic and Diluted Earnings Per Common Share HTML 52K
(Details Narrative) (10-K)
112: R102 Shareholders' Equity (Details Narrative) HTML 97K
113: R103 Shareholders' Equity (Details Narrative) (10-K) HTML 167K
114: R104 Shareholders' Equity - Schedule of Weighted HTML 60K
Average Assumptions (Details)
115: R105 Shareholders' Equity - Schedule of Weighted HTML 60K
Average Assumptions (Details) (10-K)
116: R106 Shareholders' Equity - Schedule of Restricted HTML 53K
Stock and Common Stock Unit Vested (Details)
117: R107 Shareholders' Equity - Summary of Stock Option HTML 100K
Activity (Details) (10-K)
118: R108 Shareholders' Equity - Summary of Restricted Stock HTML 71K
Unit Activity (Details) (10-K)
119: R109 Shareholders' Equity - Summary of Warrant HTML 72K
Activities (Details) (10-K)
120: R110 Income Taxes (Details Narrative) (10-K) HTML 67K
121: R111 Income Taxes - Schedule of Current and Deferred HTML 85K
Income Tax Provision (Benefit) (Details) (10-K)
122: R112 Income Taxes - Schedule of Deferred Tax Assets and HTML 91K
Liabilities (Details) (10-K)
123: R113 Income Taxes - Schedule of Reconciliation of HTML 68K
Expected Income Taxes (Details) (10-K)
124: R114 Debt (Details Narrative) HTML 155K
125: R115 Long-term Debt (Details Narrative) (10-K) HTML 84K
126: R116 Leases (Details Narrative) HTML 118K
127: R117 Leases (Details Narrative) (10-K) HTML 73K
128: R118 Leases - Schedule of Operating Lease Right-of-use HTML 74K
Assets and Liabilities (Details)
129: R119 Leases - Schedule of Operating Lease Right-of-use HTML 69K
Assets and Liabilities (Details) (10-K)
130: R120 Leases - Schedule of Maturities of Operating HTML 70K
Leases (Details) (10-K)
131: R121 Leases - Schedule of Financing Lease Right-of-use HTML 63K
Assets and Liabilities (Details)
132: R122 Leases - Schedule of Financing Lease Right-of-use HTML 62K
Assets and Liabilities (Details) (10-K)
133: R123 Leases - Schedule of Maturities of Financing HTML 60K
Leases (Details)
134: R124 Leases - Schedule of Maturities of Financing HTML 60K
Leases (Details) (10-K)
135: R125 Disposition of Site Equipment to Be Installed and HTML 66K
Fixed Assets (Details Narrative)
136: R126 Software Development Costs (Details Narrative) HTML 57K
137: R127 Goodwill (Details Narrative) HTML 55K
138: R128 Goodwill (Details Narrative) (10-K) HTML 55K
139: R129 Goodwill - Schedule of Goodwill (Details) HTML 58K
140: R130 Goodwill - Schedule of Goodwill (Details) (10-K) HTML 60K
141: R131 Accumulated Other Comprehensive Income (Details HTML 53K
Narrative)
142: R132 Accumulated Other Comprehensive Income (Details HTML 53K
Narrative) (10-K)
143: R133 Retirement Savings Plan (Details Narrative) (10-K) HTML 53K
144: R134 Subsequent Events (Details Narrative) HTML 58K
145: R135 Subsequent Events (Details Narrative) (10-K) HTML 117K
146: R136 Going Conern (Details Narrative) (Brooklyn HTML 64K
ImmunoTherapeutics, LLC)
147: R137 Basis of Presentation and Summary of Significant HTML 58K
Accounting Policies (Details Narrative) (Brooklyn
ImmunoTherapeutics, LLC)
148: R138 Merger With NTN Buzztime, Inc (Details Narrative) HTML 64K
(Brooklyn ImmunoTherapeutics, LLC)
149: R139 Fair Value of Financial Instruments (Details HTML 56K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
150: R140 Fair Value of Financial Instruments - Schedule of HTML 59K
Fair Value of Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC)
151: R141 Property and Equipment (Details Narrative) HTML 52K
(Brooklyn ImmunoTherapeutics, LLC)
152: R142 Property and Equipment - Schedule of Property and HTML 63K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC)
153: R143 Security Deposits and Other Assets (Details HTML 57K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
154: R144 Accrued Expenses (Details) (Brooklyn HTML 63K
ImmunoTherapeutics, LLC)
155: R145 Loans Payable (Details Narrative) (Brooklyn HTML 55K
ImmunoTherapeutics, LLC)
156: R146 Commitments and Contingencies (Details Narrative) HTML 96K
(Brooklyn ImmunoTherapeutics, LLC)
157: R147 Stock-Based Compensation (Details Narrative) HTML 52K
(Brooklyn ImmunoTherapeutics, LLC)
158: R148 Members' Equity (Details Narrative) (Brooklyn HTML 63K
ImmunoTherapeutics, LLC)
159: R149 Subsequent Events (Details Narrative) (Brooklyn HTML 53K
ImmunoTherapeutics, LLC)
160: R150 Going Conern (Details Narrative) (Brooklyn HTML 82K
ImmunoTherapeutics, LLC) (10-K)
161: R151 Summary of Significant Accounting Policies HTML 68K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
162: R152 Business Combination (Details Narrative) (Brooklyn HTML 59K
ImmunoTherapeutics, LLC) (10-K)
163: R153 Business Combination - Schedule of Purchase Price HTML 78K
for Acquisition (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
164: R154 Property and Equipment (Details Narative) HTML 59K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
165: R155 Property and Equipment - Schedule of Property and HTML 64K
Equipment (Details) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
166: R156 Goodwill and in Process Research and Development HTML 54K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
167: R157 Security Deposits and Other Assets (Details HTML 60K
Narrative) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
168: R158 Accrued Expenses (Details) (Brooklyn HTML 65K
ImmunoTherapeutics, LLC) (10K)
169: R159 Investor Deposits (Details Narrative) (Brooklyn HTML 51K
ImmunoTherapeutics, LLC) (10-K)
170: R160 Loans Payable and Loans Payable to Related Parties HTML 97K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
171: R161 Commitments and Contingencies (Details Narrative) HTML 126K
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
172: R162 Commitments and Contingencies - Schedule of Future HTML 68K
Commitments of Operating Lease (Details) (Brooklyn
ImmunoTherapeutics, LLC)
173: R163 Stockholders' Deficiency and Members' Equity HTML 162K
(Details Narrative) (Brooklyn ImmunoTherapeutics,
LLC) (10-K)
174: R164 Stockholders' Deficiency and Members' Equity - HTML 88K
Schedule of Stock Option Activity (Details)
(Brooklyn ImmunoTherapeutics, LLC) (10-K)
175: R165 Stockholders' Deficiency and Members' Equity - HTML 66K
Schedule of Stock Options Outstanding and
Exercisable (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
176: R166 Income Tax (Details Narrative) (Brooklyn HTML 57K
ImmunoTherapeutics, LLC) (10-K)
177: R167 Income Tax - Schedule of Income Tax Benefit HTML 80K
(Details) (Brooklyn ImmunoTherapeutics, LLC)
(10-K)
178: R168 Income Tax - Schedule of Deferred Tax Assets and HTML 57K
Liabilities (Details) (Brooklyn
ImmunoTherapeutics, LLC) (10-K)
179: R169 Subsequent Events (Details Narrative) (Brooklyn HTML 57K
ImmunoTherapeutics, LLC) (10-K)
181: XML IDEA XML File -- Filing Summary XML 369K
180: EXCEL IDEA Workbook of Financial Reports XLSX 286K
5: EX-101.INS XBRL Instance -- ntn-20200930 XML 3.48M
7: EX-101.CAL XBRL Calculations -- ntn-20200930_cal XML 462K
8: EX-101.DEF XBRL Definitions -- ntn-20200930_def XML 2.04M
9: EX-101.LAB XBRL Labels -- ntn-20200930_lab XML 2.11M
10: EX-101.PRE XBRL Presentations -- ntn-20200930_pre XML 2.35M
6: EX-101.SCH XBRL Schema -- ntn-20200930 XSD 459K
182: ZIP XBRL Zipped Folder -- 0001493152-21-001359-xbrl Zip 339K
 | Download this zipped .zip folder |
| Files: | ntn-20200930.xml ntn-20200930.xsd ntn-20200930_cal.xml ntn-20200930_def.xml ntn-20200930_lab.xml ntn-20200930_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/17/23 Eterna Therapeutics Inc. S-1 4/14/23 5:475K Broadridge Fin’l So… Inc 3/20/23 Eterna Therapeutics Inc. POS AM 3:324K Broadridge Fin’l So… Inc 3/20/23 Eterna Therapeutics Inc. 10-K 12/31/22 105:12M Broadridge Fin’l So… Inc 7/01/22 Eterna Therapeutics Inc. 10-K/A 12/31/21 92:11M Broadridge Fin’l So… Inc 4/29/22 Eterna Therapeutics Inc. S-3 4:259K Broadridge Fin’l So… Inc 4/15/22 Eterna Therapeutics Inc. 10-K 12/31/21 95:10M Broadridge Fin’l So… Inc 8/13/21 Eterna Therapeutics Inc. S-3 3:529K Broadridge Fin’l So… Inc 5/27/21 Eterna Therapeutics Inc. S-1 4:660K Broadridge Fin’l So… Inc 4/30/21 Eterna Therapeutics Inc. S-1 8:2.2M Broadridge Fin’l So… Inc 3/11/21 Eterna Therapeutics Inc. 10-K 12/31/20 84:5.2M M2 Compliance LLC/FA |